Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - Novartis - NIS793 (Details)

v3.22.1
Licensing and Other Arrangements - Novartis - NIS793 (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Oct. 20, 2021
USD ($)
Oct. 21, 2020
USD ($)
Sep. 30, 2015
USD ($)
item
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2021
USD ($)
Licensing and other arrangements                
Revenue from contracts with customers       $ 2,750 $ 19      
Novartis Note                
Licensing and other arrangements                
Reduction in debt obligation   $ 7,300            
Novartis International | License Agreement                
Licensing and other arrangements                
Agreement termination prior written notice period     180 days          
Number of performance obligations | item     1          
Cash payment received   17,700         $ 37,000  
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones $ 410,000   $ 480,000          
Revenue from contracts with customers $ 35,000 $ 25,000   0 $ 0 $ 10,000    
Royalty payment period     10 years          
Contract assets       0       $ 0
Contract liabilities       0       0
Capitalized contract costs       $ 0       $ 0